What is the role of checkpoint inhibitors in neuroendocrine neoplasms?

por Al-Toubah, Taymeyah, Pelle, Eleonora, Strosberg, Jonathan
Publicado 2020

Chemotherapy in Neuroendocrine Tumors

por Das, Satya, Al-Toubah, Taymeyah, Strosberg, Jonathan
Publicado 2021

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors

por Al-Toubah, Taymeyah, Morse, Brian, Strosberg, Jonathan
Publicado 2022

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

por Al-Toubah, Taymeyah, Strosberg, Jonathan, Hallanger-Johnson, Julie, El-Haddad, Ghassan
Publicado 2023

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms

por Al-Toubah, T., Halfdanarson, T., Gile, J., Morse, B., Sommerer, K., Strosberg, J.
Publicado 2021

HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors

por Barros, Milton J., Strosberg, Jonathan, Al-Toubah, Taymeyah, de Jesus, Victor Hugo F., Durant, Lais, Mello, Celso A., Felismino, Tiago C., De Brot, Louise, Taboada, Rodrigo G., Donadio, Mauro D., Riechelmann, Rachel P.
Publicado 2023

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation

por Eng, Cathy, Chen, Emerson Y., Rogers, Jane, Lewis, Mark, Strosberg, Jonathan, Thota, Ramya, Krishnamurthi, Smitha, Oberstein, Paul, Govindarajan, Rang, Buchschacher, Gary, Patel, Sandip, Sohal, Davendra, Al-Toubah, Taymeyah, Philip, Philip, Dasari, Arvind, Kennecke, Hagan, Stein, Stacey
Publicado 2021

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

por Vijayvergia, Namrata, Dasari, Arvind, Deng, Mengying, Litwin, Samuel, Al-Toubah, Taymeyah, Alpaugh, R. Katherine, Dotan, Efrat, Hall, Michael J., Ross, Nicole M., Runyen, Melissa M., Denlinger, Crystal S., Halperin, Daniel M., Cohen, Steven J., Engstrom, Paul F., Strosberg, Jonathan R.
Publicado 2020